Skip to main content
. 2017 Jun 20;7:3860. doi: 10.1038/s41598-017-04170-1

Figure 5.

Figure 5

AAV-shRNA treatment decreases HBsAg and HBcAg in hepatocytes of HBV-persistent mice. Serum and liver samples of mice treated with AAV2-shRNA were collected at the indicated time points during a 6 month period. Liver sections were fixed and stained for HBsAg (a) and HBcAg (c). Ten random fields were selected per slide, and the percentages of HBsAg- (b) and HBcAg-positive (d) hepatocytes were quantified using Image-Pro Plus. P < 0.05: significant difference, Data represent the mean ± SD.